- Home
- Media Center
- Press releases
- Innovative Medicine
Innovative Medicine
STELARA® Phase 3 Study Published In The Lancet Reports One Year Efficacy And Safety In Treatment Of Active Psoriatic Arthritis
Data Show Interleukin-12/23 Inhibitor STELARA Improved Joint, Soft Tissue and Skin Components of Psoriatic Arthritis
Five-Year SIMPONI Data Reported In Treatment Of Signs And Symptoms Of Moderately To Severely Active Rheumatoid Arthritis
Data from Three Pivotal Phase 3 Trials Presented at 2013 EULAR Annual Congres
Janssen, Johnson & Johnson Innovation, Announce Collaboration With Belgian Scientists To Pursue New Research In Neurodegenerative Diseases
Effort Advances Company’s Global Healthy Minds Initiative
Survey of Participants from Landmark GRACE Trial Provides Patients’ Perspectives from an HIV Clinical Study
Most Survey Participants Would Recommend Joining a Study to Others
Johnson & Johnson Pharmaceuticals Segment Poised to Continue Driving Growth with More than 10 Potential New Product Filings by 2017
Fastest growing Top 10 pharmaceutical business in the U.S., Europe & Japan in 2012, 12 consecutive quarters of operational sales growth in the Pharmaceuticals segment• Current plans are for new products to account for nearly half of the total sales in the Pharmaceuticals segment by 2017, Continued commitment to addressing most serious global unmet medical needs to help transform the lives of patients, R&D strategy builds on strong internal research and external innovation, Late stage pipeline features potential breakthrough therapies that will help transform patient care and sustain future growth
SIMPONI® (GOLIMUMAB) Receives FDA Approval For Ulcerative Colitis
First and Only Subcutaneous Biologic Treatment Approved to Induce and Maintain Clinical Response and Improve Endoscopic Appearance of the Mucosa During Induction